<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04087915</url>
  </required_header>
  <id_info>
    <org_study_id>FORWARD</org_study_id>
    <nct_id>NCT04087915</nct_id>
  </id_info>
  <brief_title>Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)</brief_title>
  <acronym>FORWARD</acronym>
  <official_title>A Perspective, Cohort Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab is Used in Combination With Statin Therapy In Patients With High Risk Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective was to evaluate the effect of treatment with evolocumab on the risk for&#xD;
      cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or&#xD;
      coronary revascularization, whichever occurs first, in patients with high risk coronary&#xD;
      artery disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of main adverse cardiovascular and cerebrovascular events (MACCE)</measure>
    <time_frame>1 year</time_frame>
    <description>MACCE will include all-cause death, cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, or coronary revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in LDL-C</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Reduction in LDL-C reduction in LDL-C after 1 month, 3 months, 6 months and 12 months of therapy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>High Risk Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>High risk coronary artery disease</arm_group_label>
    <description>Participants with high risk coronary artery disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference</description>
    <arm_group_label>High risk coronary artery disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with high risk coronary artery disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥ 18 years of age&#xD;
&#xD;
          -  Coronary artery disease at high risk (Syntax Score ≥ 33)&#xD;
&#xD;
          -  Patients had to have a fasting LDL cholesterol level of 1.4 mmol per liter while they&#xD;
             had been taken an optimized regimen of lipid-lowering therapy for at least 4 weeks,&#xD;
             which was defined as preferably a high intensity statin but must have been at least&#xD;
             atorvastatin at a dose of 20 mg daily or its equivalent, with or without ezetimibe.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  New York Heart Association (NYHA) class III or IV, or last known left ventricular&#xD;
             ejection fraction &lt; 30%&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Uncontrolled or recurrent ventricular tachycardia&#xD;
&#xD;
          -  Untreated hyperthyroidism or hypothyroidism&#xD;
&#xD;
          -  Homozygous familial hypercholesterolemia&#xD;
&#xD;
          -  LDL or plasma apheresis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yujie Zhou, PhD,MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yujie Zhou, PhD,MD</last_name>
    <phone>8613901330652</phone>
    <email>azzyj12@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujie Zhou, PhD,MD</last_name>
      <phone>8613901330652</phone>
      <email>azzyj12@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Yujie Zhou</investigator_full_name>
    <investigator_title>PhD,MD</investigator_title>
  </responsible_party>
  <keyword>High cholesterol</keyword>
  <keyword>Treatment for high cholesterol</keyword>
  <keyword>Lowering cholesterol</keyword>
  <keyword>Lowering high cholesterol</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

